Hydrophobic IOL outcomes
Good visual outcomes with new heparin-coated IOL.


Roibeard O’hEineachain
Published: Saturday, April 1, 2017
The prospective randomised controlled trial involved 64 eyes of 32 cataract patients who underwent implantation of either the CT LUCIA 601PY or SN60WF IOL between June 2014 and October 2015However, he noted that the new lens performed less well than the AcrySof lens in terms of PCO. At 12 months, only around half as many eyes were PCO-free in the CT LUCIA group as in the SN60WF group and three patients with the new lens required a YAG capsulotomy. However, he added that the design of the CT LUCIA lens has been modified since the trial and now has a sharper optic edge, which should reduce the incidence of the complication in the future. Regarding glistenings, he noted that all of the new Zeiss IOLs at his centre remained glistening-free at one year, whereas glistenings were present in 13 of the older Alcon lenses. There were, however, some glistenings reported in the new lenses in a large multicentre trial, he said. Tobias Brockmann: tobias.brockmann@charite.de
Tags: heparin coated iol
Latest Articles
Making Female Leadership More than a Moment
A remarkable global confluence of women in key positions.
ESCRS Talks Technology at AAO
Europe adopts technological advances, US still waiting for lenses and lasers.
Sorting Out Simultaneous Vision IOLs
The ESCRS Eye Journal Club discuss a new landmark paper on IOL classification and the need for harmonisation of terminology for presbyopic IOLs.
Big Advantages to Small-Aperture IOLs
Small-aperture IOLs offer superior image quality with increased range of focus.
Prioritising Self-Care
Benefits of maintaining physical, emotional, and mental health extend beyond the personal sphere.
Valuing Clinical Trial Design
How inclusivity and diversity can enhance scientific accuracy in research.
Knowing Iris Repair: Using Iridodiathermy in Iris Surgery
Prepare for decentred pupils and uneven irides in multiple situations.
Neuroprotectant Treatment for MacTel Type 2
Intravitreal implant releasing ciliary neurotrophic factor found safe and effective in pivotal trials.